Teva lied about opioid role, New York says
New York's attorney general on Monday said Teva Pharmaceutical Industries Ltd (TEVA.TA) lied to evade accountability for helping fuel the state's opioid crisis, and should be restored to litigation where the Israeli company's U.S. unit had been found liable.
In a court filing, Attorney General Letitia James said new evidence showed that a senior Teva tax executive had in a sworn affidavit made "demonstrably false" representations that the parent did not promote or sell opioids in the United States, or control Teva Pharmaceuticals USA's finances or activities.
"This new evidence shows an even greater disregard for the pain and destruction that this company fueled," and may constitute a "fraud on the court," James said.
The attorney general also said Teva's use of offshore accounts to shelter potentially large sums of money from its American business created "real concern" the company might not pay damages following a Dec. 30 Suffolk County jury verdict that the U.S. unit violated state public nuisance laws.
In a statement, Teva said: "Teva denies misleading the court, and after the court is fully briefed we expect the judge to rule in our favor."
The company said in May it may have to pay $2.6 billion to settle U.S. opioid lawsuits nationwide.
James' lawsuit is among more than 3,300 filed by state, local and Native American tribal governments accusing drugmakers of downplaying opioid addiction, and distributors and pharmacies of ignoring red flags about how opioids were being misused.
The attorney general said she has reached $539 million of settlements with four drugmakers, including Johnson & Johnson (JNJ.N) and Abbvie Inc , and $1.18 billion of settlements with drug distributors AmerisourceBergen Corp (ABC.N), Cardinal Health Inc and McKesson Corp (MCK.N).
Teva was accused by James, Nassau County and Suffolk County of using misleading marketing for opioids, including by pushing them for off-label use.
The case focused on Teva's generic drugs and the Actiq and Fentora cancer pain treatments. Teva's parent company was dismissed as a defendant in December 2019.
A damages trial has yet to be held.
"This new evidence shows an even greater disregard for the pain and destruction that this company fueled," and may constitute a "fraud on the court," James said.
The attorney general also said Teva's use of offshore accounts to shelter potentially large sums of money from its American business created "real concern" the company might not pay damages following a Dec. 30 Suffolk County jury verdict that the U.S. unit violated state public nuisance laws.
In a statement, Teva said: "Teva denies misleading the court, and after the court is fully briefed we expect the judge to rule in our favor."
The company said in May it may have to pay $2.6 billion to settle U.S. opioid lawsuits nationwide.
James' lawsuit is among more than 3,300 filed by state, local and Native American tribal governments accusing drugmakers of downplaying opioid addiction, and distributors and pharmacies of ignoring red flags about how opioids were being misused.
The attorney general said she has reached $539 million of settlements with four drugmakers, including Johnson & Johnson (JNJ.N) and Abbvie Inc , and $1.18 billion of settlements with drug distributors AmerisourceBergen Corp (ABC.N), Cardinal Health Inc and McKesson Corp (MCK.N).
Teva was accused by James, Nassau County and Suffolk County of using misleading marketing for opioids, including by pushing them for off-label use.
The case focused on Teva's generic drugs and the Actiq and Fentora cancer pain treatments. Teva's parent company was dismissed as a defendant in December 2019.
A damages trial has yet to be held.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.